Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use and abuse of allopurinol.

Literature DB >> 3607420

Use and abuse of allopurinol.

J S Cameron, H A Simmonds.

Abstract

Entities: Chemical

Mesh：

Substances：
Allopurinol

Year: 1987 PMID： 3607420 PMCID： PMC1246665 DOI： 10.1136/bmj.294.6586.1504

Source DB: PubMed Journal: Br Med J (Clin Res Ed) ISSN： 0267-0623

× No keyword cloud information.

39 in total

1. THE USE OF ALLOPURINOL (HPP) TO CONTROL HYPERURICEMIA IN PATIENTS ON CHRONIC INTERMITTENT HEMODIALYSIS.

Authors: C P HAYES; E N METZ; R R ROBINSON; R W RUNDLES
Journal: Trans Am Soc Artif Intern Organs Date: 1965

2. Granulomatous interstitial nephritis associated with allopurinol therapy.

Authors: P Magner; J Sweet; R A Bear
Journal: CMAJ Date: 1986-09-01 Impact factor: 8.262

3. [Allopurinol toxicity. Apropos of 1 case].

Authors: C Guérin; C Genin; J Toulon; J C Sabatier; G Leroy; F Berthoux
Journal: Nephrologie Date: 1986

4. Renal clearance of oxipurinol, the chief metabolite of allopurinol.

Authors: G B Elion; T F Yü; A B Gutman; G H Hitchings
Journal: Am J Med Date: 1968-07 Impact factor: 4.965

5. The development of allopurinol.

Authors: R W Rundles
Journal: Arch Intern Med Date: 1985-08

6. Renal xanthine stone in Lesch-Nyhan syndrome treated with allopurinol.

Authors: A Ogawa; K Watanabe; N Minejima
Journal: Urology Date: 1985-07 Impact factor: 2.649

7. The effect of dietary protein on the clearance of allopurinol and oxypurinol.

Authors: W G Berlinger; G D Park; R Spector
Journal: N Engl J Med Date: 1985-09-26 Impact factor: 91.245

8. Randomized trial of allopurinol in the prevention of calcium oxalate calculi.

Authors: B Ettinger; A Tang; J T Citron; B Livermore; T Williams
Journal: N Engl J Med Date: 1986-11-27 Impact factor: 91.245

9. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors: K R Hande; R M Noone; W J Stone
Journal: Am J Med Date: 1984-01 Impact factor: 4.965

10. On the metabolism of allopurinol. Formation of allopurinol-1-riboside in purine nucleoside phosphorylase deficiency.

Authors: S Reiter; H A Simmonds; D R Webster; A R Watson
Journal: Biochem Pharmacol Date: 1983-07-15 Impact factor: 5.858

16 in total

1. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy.

Authors: G M Peterson; R R Boyle; H W Francis; N W Oliver; J Paterson; R J von Witt; G R Taylor
Journal: Eur J Clin Pharmacol Date: 1990 Impact factor: 2.953

2. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.

Authors: R O Day; J O Miners; D J Birkett; A Whitehead; D Naidoo; J Hayes; E Savdie
Journal: Br J Clin Pharmacol Date: 1988-10 Impact factor: 4.335

3. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.

Authors: K Turnheim; P Krivanek; R Oberbauer
Journal: Br J Clin Pharmacol Date: 1999-10 Impact factor: 4.335

4. Allopurinol, erythema multiforme, and renal insufficiency.

Authors: A Kumar; N Edward; M I White; P W Johnston; G R Catto
Journal: BMJ Date: 1996-01-20

5. Acute renal failure from xanthine nephropathy during management of acute leukemia.

Authors: Christopher LaRosa; Laura McMullen; Suzanne Bakdash; Demetrius Ellis; Lakshmanan Krishnamurti; Hsi-Yang Wu; Michael L Moritz
Journal: Pediatr Nephrol Date: 2006-10-13 Impact factor: 3.714

6. Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. I. Uric acid kinetics.

Authors: W Löffler; R Landthaler; J X de Vries; I Walter-Sack; A Ittensohn; A Voss; N Zöllner
Journal: Clin Investig Date: 1994-12